1. Generics Bulletin
  2. >>Legal & IP

IGBA Favors WHO System Over Originator Database

 
• By Dave Wallace

In the final of three exclusive interviews, IGBA chair Jim Keon and secretary general Suzette Kox provide the latest update on global issues affecting the off-patent industries, including originator intellectual-property tactics in the form of the WIPO’s and IFPMA’s Pat-INFORMED database.

Digital globe
The IGBA’s Secretary General And Chair Give Us The Latest On Global Issues Affecting The Generics And Biosimilars Industries • Source: Shutterstock

As the global industry association for generics and biosimilars companies, the International Generic and Biosimilar medicines Association (IGBA) is perfectly positioned to take an international view of the intellectual property landscape.

Recently, IGBA chair Jim Keon – who is also president of the Canadian Generic Pharmaceutical Association (CGPA) – and newly-appointed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Cigna Claims BMS Tied Revlimid Settlements to Pomalyst ‘Pay-for-Delay’ Scheme

 
• By Dean Rudge

Among other schemes, Cigna alleges that Celgene and parent Bristol Myers Squibb “paid” generic challengers – via lucrative Revlimid profit-sharing agreements – to delay generic market entry for Pomalyst until 2026, unlawfully extending their monopoly and overcharging purchasers.

US Supreme Court Requests Solicitor General Input On Hikma Skinny Label Case

 
• By Dean Rudge

The US Supreme Court is seeking a brief “expressing the views of the United States,” following the US Federal Circuit’s decision to reopen Amarin’s claim of induced infringement against Hikma relating to its ‘skinny-label’ generic Vascepa (icosapent ethyl) product.

‘Disappointed’ Lipella Seeks Alternatives Following Nasdaq Delisting

 
• By Dean Rudge

Clinical-stage reformulation specialist Lipella Pharmaceuticals has insisted that “our commitment to our shareholders, our mission, and our clinical goals has not changed” after its common stock was delisted from the Nasdaq Capital Market.

AAM Celebrates Court Backing Over Minnesota Pricing Law

 
• By Dave Wallace

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.

More from Generics Bulletin

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Where Art Thou Celltrion? Kabi Pushes Past With US Denosumab Launches

 
• By Dean Rudge

Fresenius Kabi has become the second company to launch US denosumab biosimilars, taking its current biosimilars portfolio up to six products.

‘America Leans On Hikma’ And Its $1bn Domestic Drug Manufacturing Investment

 
• By Urtė Fultinavičiūtė

Claiming to be a top-three supplier of sterile injectables in the US, Hikma intends to invest $1bn over the next five years to further expand its American manufacturing base, as the threat of tariffs still looms.